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ABSTRACT
We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched
unrelated granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cell (G-PBMC)
grafts after fludarabine 90 mg/m2, 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil
(MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg twice daily orally. Graft rejection was 15%; the
cumulative probability of acute graft-versus-host disease (GVHD) was 52%. According to MMF pharmacoki-
netic studies, which showed a short half-life of its active metabolite, mycophenolic acid, we increased MMF
dosing from 15 mg/kg twice daily to 15 mg/kg 3 times daily to increase immunosuppression and reduce the
incidence of both graft rejection and acute GVHD. Among 103 patients so treated, graft rejection occurred in
5%, whereas acute GVHD remained at 53%. Outcomes were compared with results of previous G-PBMC
recipients given MMF twice daily. Infection rates were slightly higher with MMF 3 times daily than with MMF
twice daily. Nevertheless, 2-year nonrelapse mortality and overall and progression-free survivals were similar
for MMF 3-times-daily and twice-daily patients (19%, 58%, and 49% versus 20%, 48%, and 37%, respectively).
Nonmyeloablative conditioning with postgrafting cyclosporine and MMF given 3 times daily allowed 95%
durable engraftment of unrelated donor G-PBMC grafts.
© 2006 American Society for Blood and Marrow Transplantation
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vNTRODUCTION
In 2003, we reported initial results in 71 patients
ith advanced hematologic malignancies who received
LA-matched unrelated granulocyte colony-stimulat-
ng factor–mobilized peripheral blood mononuclear cell
G-PBMC; 15%) grafts using a nonablative conditioning m
54egimen that combined 3 doses of ﬂudarabine (FLU)
nd 2 Gy of total body irradiation (TBI) [1]. Postgrafting
mmunosuppression, aimed both at facilitating alloge-
eic hematopoietic engraftment and controlling graft-
ersus-host disease (GVHD), consisted of twice-daily
ycophenolate mofetil (MMF) for 3 months and twice-
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Nonmyeloablative Unrelated Donor Transplantation
Baily cyclosporine (CSP) for 6 months. The nonablative
egimen was chosen because patients were deemed too
ld and/or too ill to tolerate conventional high-dose
ematopoietic cell transplantation (HCT). With follow-
ps ranging from 0.5 to 2.4 years, the overall survival of
he heterogenous group of patients was 57%, and clear
vidence of graft-versus-tumor (GVT) effects was ob-
erved. Even so, 43% of patients relapsed or progressed,
nd 27% died from their underlying diseases. Some,
lthough not all, of the relapses were the consequence of
15% rate of graft rejection, which was followed by
utologous hematopoietic recovery in all but 2 patients.
ther causes of failure included complications from
cute GVHD, which was seen in 52% of patients.
This study included 103 patients with malignan-
ies given unrelated HCT and was designed to address
oth graft rejection and acute GVHD by introducing
change to the original protocol: increasing MMF
osing from 2 to 3 times daily. This change was
rompted both by observations on the importance of
MF for engraftment, originally made in preclinical
anine studies [2], and by the short (3-hour) half-life
f mycophenolic acid, the active metabolite of MMF,
n the prior clinical study [1]. We hypothesized that
ore frequent MMF dosing would overcome the dis-
dvantage of the short mycophenolate acid half-life
nd provide improved immunosuppression.
This article describes the results in the 103 new
atients and then compares the observed incidences of
raft rejection and acute GVHD with those among
he 71 previously reported G-PBMC recipients. Fi-
ally, the combined data of all 174 G-PBMC recipi-
nts from both studies are analyzed for outcomes.
ATERIALS AND METHODS
ligibility Criteria
Patients in this study were treated at 11 academic
enters including the Fred Hutchinson Cancer Re-
earch Center (FHCRC), University of Washington
edical Center, Seattle Children’s Hospital and Re-
ional Medical Center, Seattle Veterans Administration
edical Center, Stanford University, Baylor University,
niversity of Leipzig (Germany), University of Utah,
regon Health and Science University, University of
olorado, Emory University, Medical College of
isconsin, and the University of Turin (Italy): the
HCRC acted as the coordinating center. The insti-
utional review board at each center approved FH-
RC protocol 1641. Informed written consent was
btained from all patients. All patients older than 50
ears were eligible for the study (n  70). Patients
ounger than 50 years were included if they had co-
orbid conditions that excluded them from conven-
ional allogeneic HCT. Conditions included failed
revious high-dose autologous HCT (n  18), recent w
B&MTneumonitis (n  1), liver dysfunction (n  2), car-
iomyopathy (n  1), dyskeratosis congenita (n  1),
enal dysfunction (n  1), metastatic renal cell carci-
oma (n  4), morbid obesity (n  1), and morbidity
rom multiple prior chemotherapies (n  2). In 3
nstances, inclusion in the protocol was due to patient
reference.
Excluded from the protocol were patients who
ere pregnant or who had rapidly progressive B- or
-cell malignancies, myeloid malignancies with 5%
arrow blasts [1], a Karnofsky performance status
f 50%, decompensated liver disease, a corrected
ulmonary diffusion capacity of40%, a cardiac ejec-
ion fraction of 35%, or serologic evidence of infec-
ion with the human immunodeﬁciency virus. No ex-
lusions were made for renal insufﬁciency or active
acterial or fungal infections, although fungal pneu-
onitis needed to be stable or improved after 1 month
f azole therapy.
LA Typing and Matching
One hundred three donors and recipients were
elected on the basis of matching by intermediate- and
igh-resolution typing for HLA-A, -B, and -C and
igh-resolution typing for -DRB1 and -DQB1 [3].
inety-three pairs were matched at the allele level for
oth HLA class I and II antigens. Ten pairs were
ismatched: 6 for 1 HLA-C allele, 3 for 1 HLA-B
llele, and 1 for an HLA-A allele each.
atient Characteristics
One hundred four sequential patients were en-
olled on FHCRC protocol 1641 between October
002 and August 2003. One patient withdrew consent
uring FLU conditioning and did not receive TBI or
he infusion of unrelated G-PBMC. Only data from
he 103 patients who received HCT are presented.
atient characteristics are shown in Table 1. The
edian patient age was 54 years (range, 18-69.6
ears). The patients’ diagnoses included myelodyspla-
ia (MDS; n  9), acute myeloid leukemia (n  23),
cute lymphocytic leukemia (n  1), chronic my-
loid leukemia (CML; n  5), non-Hodgkin lym-
homa (NHL; n  24), myeloproliferative syn-
rome (MPS; n  3), chronic lymphocytic leukemia
CLL; n  13), Hodgkin disease (HD; n  8),
ultiple myeloma (n  11), renal cell carcinoma
n  4), and Waldenström macroglobulinemia (n  2).
he median time from diagnosis to transplantation
as 27 months (range, 3-191 months).
onditioning Regimen and Postgrafting
mmunosuppression
FLU was given intravenously at 30 mg/m2/d on
ays 4, 3, and 2 before HCT, and 2 Gy of TBI
as delivered at 0.07 Gy/min from a linear accelerator
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4n day 0. Immunosuppressive therapy with oral CSP
.25 mg/kg twice a day was started on day 3, and
MF 15 mg/kg orally 3 times a day was started 4 to
hours after HCT on day 0. CSP levels were mea-
ured by immunoassay and were targeted to 400 to
00 ng/mL for the ﬁrst month and 300 ng/mL there-
fter. CSP and MMF were administered intravenously
able 1. Patient and Disease Characteristics
Variable
3-Tim
M
o. patients
edian age, y (range) 54 (
edian No. of preceding therapies (range) 4 (
edian follow-up after HCT, mo (range) 21.4 (
receding HCT
edian No. CD34 cells  106/kg (range) 7.3 (
edian No. CD3 T cells  108/kg (range) 2.7 (
onor HLA match (No. patients)
HLA allele match
HLA allele mismatch
iagnosis and status at HCT (No. patients)
AML/ALL (total)
CR1
CR2
>CR3
Rel/Ref/induction failure
MDS (total)
RA
RAEB/CR1 1
RAEB-T
AML CR1/CR2 3
AML Rel/Ref 0
CMML PR/Ref/induction failure 0
CML (total)
CP/AP/BC 3
CP-2
MPS (total)
ET
AMM/transformation 1
AML CR
NOS
Indolent/high-grade NHL (total)
CR/PR 9
Stable
Ref/Rel 6
CLL (total)
FLU sensitive
FLU refractory
HD (total)
CR/PR 1
Rel/Ref 1
MM (total)
CR/PR/Ref 2
Waldenström
Renal cell carcinoma
igh risk diagnoses* 90 (
LL indicates acute lymphocytic leukemia; AML, acute myeloid le
formation; AP, accelerated phase; CLL, chronic lymphoid leu
complete remission; ET, essential thrombocytosis; HD, Hodg
MPS, myeloproliferative syndrome; NHL, non-Hodgkin ly
refractory anemia; RAEB, refractory anemia with excess blasts
refractory; Rel, relapsed; BC, blast crisis; CMML, chronic m
High-risk malignancies include advanced-stage AML, ALL, MDSf patients were not able to tolerate oral medications. t
56or patients without manifestations of GVHD, MMF
as tapered at day 40 over 56 days, and CSP was
apered at day 100 over 80 days.
ollection of Hematopoietic Cells
Donor G-PBMC collections were conducted by Na-
ily
Twice-Daily MMF Overall
71 174
) 54 (18-70) 54 (17-70)
3 (0-11) 3 (0-12)
38.7 (18.3-51.6) 24.9 (6-51.6)
30% 34%
3) 7.0 (1.2-24.4) 7.2 (0.8-26.3)
) 2.6 (0.8-5.8) 2.6 (0.3-9.3)
58 151
13 23
13 37
6 14
2 15
4 5
1 3
17 26
3 5
2/0 3/3
3 3
2/1 5/1
2/1 2/1
1/1/1 1/1/1
10 15
6/1/0 9/3/0
3 3
5 7
2 2
0/1 1/1
0 1
2 3
10 34
2/2 11/8
0 1
4/2 10/4
5 18
1 1
4 17
4 12
0/2 1/5
0/2 1/5
7 18
0/4/3 2/10/6
0 2
0 4
54 (76%) 144 (83%)
a; AMM, transformation-agnogeneic myeloid metaplasia in trans-
; CML, chronic myelogenous leukemia; CP, chronic phase; CR,
ease; MDS, myelodysplastic syndrome; MM, multiple myeloma;
a; NOS, not otherwise speciﬁed; PR, partial remission; RA,
-T, refractory anemia with excess blasts in transformation; Ref,
onocytic leukemia.
in accelerated phase or blast crisis, or B-cell malignancies.es–Da
MF
103
17-69.6
0-12)
6-34.7)
37%
0.8-26.
0.3-9.3
93
10
24
8
13
1
2
9
2
/3
0
/0
/0
/0/0
5
/2/0
0
3
0
/0
1
1
24
/6
1
/2
13
0
13
8
/3
/3
11
/6/3
2
4
87%)
ukemi
kemia
kin dis
mphom
; RAEB
yelomional Marrow Donor Program standards. Red blood
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Bell (RBC) depletions of grafts were performed for pa-
ients with high titers of antidonor isohemagglutinins.
portion of the G-PBMC product, containing at least
 107CD3 cells per kilogram, was cryopreserved
or potential use as donor lymphocyte infusions
DLIs).
upportive Care
At most collaborating institutions, patients were
een in the ambulatory care setting except during
he scheduled infusion of the hematopoietic cells and
henever transplantation complications mandated
loser medical supervision or therapy. All patients at
he University of Leipzig were treated for at least 1
onth on a hematology ward per institutional prac-
ice. Supportive care measures have been previously
escribed [1].
VHD Grading and Therapy
The GVHD grade was assigned by local investi-
ators by using standard criteria [4-6]. Treatment of
cute GVHD was conducted according to each insti-
ution’s standard practice guidelines.
reatment of Persistent/Progressive
r Relapsed Malignancies
Progressive or relapsed malignancies in the ab-
ence of severe manifestations of acute or chronic
VHD were treated by rapid discontinuation of sys-
emic immunosuppression to initiate GVT effects
7,8]. In addition, 5 patients received DLI for disease
rogression (n  3) [9], low (40%) CD3 chimerism
n  1) [10], or Epstein-Barr virus lymphoprolifera-
ive disease in donor B cells (n  1).
himerism Analyses
Nucleated cells from the marrow and T cells and
ranulocytes from the peripheral blood were isolated
y using ﬂow cytometry on days 28, 56, 84, 180, 365,
nd 545 and then yearly after HCT for chimerism
nalyses. Percentages of donor-host cell chimerism
evels for recipients of sex-mismatched HCT were
valuated by ﬂuorescent in situ hybridization for X
nd Y chromosomes [11], whereas those for recipients
f sex-matched HCT were determined by polymerase
hain reaction–based ampliﬁcation of variable number
andem repeat sequences unique to donors and hosts
12]. Fluorescent in situ hybridization tests were per-
ormed, whenever possible, because of their slightly
etter sensitivity and their faster turnaround time, the
atter being important in cases of suspected graft re-
ection. Donor-host chimerism was assessed exclu-
ively by variable number tandem repeat for all pa-
ients treated at Stanford University. Chimerism was
etermined by visual inspection of silver-stained aga-
ose gels with a standard error of 1% to 5%. t
B&MTtudy End Points
Data were analyzed as of December 1, 2004. The
primary objectives of this protocol were to (1) re-
uce the risk of true graft rejection in patients without
receding chemotherapy to 20% and in those with
receding chemotherapy to 10% and (2) reduce the
isk of grade II to IV acute GVHD in patients with
ustained engraftment to 35%. Secondary end
oints included survival and progression-free survival.
omparison of Results in Current and Previously
ublished G-PBMC Recipients
Results in the previously published 71 G-PBMC
ecipients on FHCRC protocol 1463 (MMF twice
aily) were updated as of December 2004. Their char-
cteristics are also shown in Table 1. Graft rejection
nd acute GVHD incidences in patients on both the
urrent protocol (1641) and the previous protocol
1463) were compared, and then data from both pa-
ient groups were combined for multivariate outcome
nalyses.
tatistical Methods
The percentages of patients with sustained en-
raftment (based on detection of 5% donor CD3
himerism) were compared by the 2 test. Overall and
rogression-free survivals were estimated by the Kaplan-
eier method. Cumulative incidence estimates were cal-
ulated for graft rejection, acute GVHD, relapse, and
onrelapse mortality. Hazard ratios were estimated
rom Cox regression models. All P values were derived
rom likelihood ratio statistics and were 2 sided. Pa-
ients were considered to have died of nonrelapse causes
f there was no evidence of disease relapse or progres-
ion. Patients with persistent disease were considered at
isk for nonrelapse mortality. Disease responses and
rogression were deﬁned by standard criteria. Neu-
rophil recovery was deﬁned as the ﬁrst of 3 consec-
tive days with neutrophil counts 0.5  109/L.
latelet recovery was deﬁned as the ﬁrst of 3 consec-
tive days with platelet counts 20  109/L without
ransfusion support.
utcome Analysis of Combined Current and
revious Data
For the evaluation of global risk factors for rejec-
ion, low chimerism, relapse/progression, and overall
nd progression-free survival, updated data from 71
-PBMC recipients given MMF twice daily were
ombined with the data from the 103 patients given
MF 3 times daily. Multivariate models were con-
tructed in a stepwise fashion by using a threshold
igniﬁcance level of .05 for inclusion in the model.
ultivariate P values for a variable were based on
djustment for all other variables in the model. Pre-
ransplantation factors considered in this analysis in-
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4luded diagnosis, disease type, CD34 dose, CD3 dose,
atient sex, donor sex, sex mismatch, HLA class I
llele mismatch, preceding transfusions, preceding
hemotherapy, and preceding autologous transplanta-
ion. Of note, 2 additional patients in the previous
ohort experienced late graft rejections (400 and 1123
ays after HCT, respectively), thus bringing the over-
ll graft rejection rate to 18% (13/71).
ESULTS
ngraftment
The median CD34 and CD3 cell doses of G-PBMC
ere 7.3  106 (range, 0.8-26.3  106) and 2.7  108
range, 0.3-9.3  108) per kilogram recipient body
eight, respectively (Table 1). One of 103 patients stud-
ed did not recover neutrophil counts to0.5 109/L
early graft rejection), and a second patient had a loss
f neutrophil production after initial recovery (late
raft failure along with decreasing donor CD3 chi-
erism). This patient was then given previously
tored autologous G-PBMC but died of acute respi-
atory distress syndrome before recovery of autolo-
ous cells. Eighteen (16%) of 103 patients did not
evelop neutropenia (0.5  103/L). The median
eutrophil nadir was 100 cells per microliter, and the
uration of neutropenia was 7 days (range, 0-44 days).
ixty-six (64%) of the 103 patients did not develop
hrombocytopenia (20  103/L). The median
latelet nadir was 32 000/L, and the median time to
latelet recovery 20  103/L was 0 days (range,
-27 days). The median numbers of RBC and platelet
ransfusions were 6 (range, 0-32) and 2 (range, 0-48),
espectively. RBC and platelet transfusions were not
equired in 21 (20%) and 60 (58%) of the 103 patients,
espectively.
Initial donor engraftment at day 28 (deﬁned as5%
onor T-cell chimerism) was observed in 101 (98%)
f the 103 patients and was sustained in 98 patients
95%). The sustained engraftment rate was higher for
atients with preceding chemotherapy (88 of 91; 97%)
han in those without such therapy (10 of 12; 83%; P
05). The 97% engraftment rate for the 88 patients with
receding chemotherapy met the 95th percentile conﬁ-
ence intervals set forth in the protocol objectives for
chieving 10% rejection (P  .05). However, there
as insufﬁcient statistical power to demonstrate that
he 17% rejection rate among the 12 patients without
receding chemotherapy truly resulted in a rejection
ate of 20% (P  .33). Overall, 5 patients with acute
yeloid leukemia, mantle cell lymphoma, multiple
yeloma, and CML in chronic phase (CP; n  2)
xperienced graft rejection (2 complicated by aplasia).
hree of these patients had successful engraftment
fter 1 (n  1) and 2 (n  2) further unrelated donor
CT attempts with FLU 90 mg/m2 and 3 to 4 Gy of
58BI or cyclophosphamide 120 mg/kg, FLU 150 mg/
2, and Thymoglobulin 7.5 mg/kg. Unfortunately, 1
f these patients died of sepsis. The patients with
ML-CP refused to consider a second transplanta-
ion. Most patients had high degrees of donor chi-
erism levels in nucleated marrow cells and periph-
ral blood granulocytes and T cells at day 28, with
radual increases over the subsequent 730 days
Figure 1A).
oxicities and Nonrelapse Mortality
Twenty of the 103 patients were not hospitalized.
ighty-three (81%) required a median of 11 days
range, 0-100 days) of hospitalization. Alopecia, mu-
ositis, and veno-occlusive disease were not observed.
he numbers of grade III and IV organ toxicities
ithin the ﬁrst 100 days are shown in Table 2. Fifty-
ix (54%) patients experienced 107 grade III events,
nd 17 patients experienced 20 grade IV toxicity events.
igure 1. A, Median percentages of granulocyte (CD33), T-cell
CD3), and whole nucleated marrow cell (BM) chimerism levels
fter HCT in 103 patients given G-PBMC grafts and MMF every
hours. B, Median percentages of donor T-cell chimerism levels
or patients given MMF every 8 (TID) or 12 (BID) hours a day. The
ars in (B) indicate the 95th percentile.
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Bepatic complications (34% of patients) were the
ost frequent organ toxicity; 82% of these were
eversible grade III hyperbilirubinemia typically re-
ulting from cholestasis lenta and bilirubin transport
ysfunction due to protocol-speciﬁed high therapeutic
erum levels of CSP within the ﬁrst month of HCT
13]. No grade IV hepatic events were observed. The
0 grade IV events included cardiac (n  6), pulmo-
ary (n  6), neurologic (n  4), and other (n  4)
oxicities.
nfection Rates in the First 100 Days after HCT
For MMF 3-times-daily patients, the documented
able 2. Numbers of Grade III and IV Nonhematopoeitic Toxicities wi
Organ System Event
ardiovascular Hypertension
Hypotension
Atrial dysrhythmia
Chest pain
Infarction
Congestive heart failure
Deep venous thrombosis
Cardiac arrest
ndocrine Syndrome of inapropriate antidiu
astrointestinal Nausea and vomiting
Diarrhea
Constipation
Stomatitis
emorrhage Hematuria
Conjunctival
Right groin (procedure related)
Gastrointestinal
Subdural hematoma
epatic Hyperbilirubinemia
Elevated transaminases
Hypoalbuminemia
Lactate dehydrogenase elevation
etabolic Hyperglycemia
Electrolyte abnormality
eurologic Cerebral vascular accident/infarc
Mental status change
Syncope
Depression
Weakness
Insomnia
Neuropathy
Seizures
ulmonary Pneumonia
Infiltrates
Dyspnea
Acute respiratory distress syndro
Hypoxia
Pleural effusion
Pulmonary failure
enal/genitourinary Bladder spasms
Dysuria
Azotemia
Renal tubular acidosis
econdary malignancy Epstein-Barr virus lymphoprolife
Total
Toxicity was assessed by using the modiﬁed Common Toxicity Cates per 100 patient days of viral (including cytomeg- a
B&MTlovirus reactivation), fungal, and bacterial infections
ere 0.86, 0.26, and 1.05 (total infection rate of 2.17),
espectively. The rate per 100 patient days of pre-
umed clinical infections was 0.88.
Nineteen (18.5%) of the 103 patients died from
onrelapse causes. The cumulative probability of non-
elapse mortality was 19% at 2 years. Causes of death
ncluded grade IV GVHD (n 3), GVHD complicated
y thrombotic thrombocytopenic purpura (n  1), in-
ections or sepsis syndrome with GVHD (n  3),
nfections or sepsis without GVHD (n 7), aspiration
neumonitis (n  1), acute respiratory distress after
raft failure (n  1), ventricular dysrhythmia (n  2),
0 Days of HCT (n  103)
No. Events*
Toxicity Grade III Toxicity Grade IV
1 0
4 2
3 0
1 0
0 1
3 0
3 0
0 3
ormone 1 1
5 1
2 0
1 0
1 0
3 0
1 0
1 0
1 0
0 1
29 0
4 0
1 0
1 0
1 0
1 0
0 2
1 1
0 0
1 0
2 0
1 0
1 0
6 1
2 0
1 0
4 0
0 1
5 2
1 0
0 3
1 0
1 0
11 0
1 0
isorder 0 1
107 20
of the National Institutes of Health.thin 10
retic h
t
me
rative dnd suspected myocardial infarction (n  1).
459
GG
1
G
i
e
5
S
3
p
K
w
a
t
7
S
P
r
s
e
r
2
w
a
w
r
a
e
r
m
i
p
(
m
H
r
T
f
l
s
4
M
D
s
p
r
c
p
D
s
l
2
(
o
F
s
F
G
g
M. B. Maris et al.
4raft-versus-Host Disease
The cumulative incidence of grades II to IV acute
VHD was 53% (Figure 2A). Of this, 39% was grade II,
0% was grade III, and 4% was grade IV acute
VHD. Chronic GVHD requiring therapy occurred
n 50 patients. The cumulative probability of chronic
xtensive GVHD at 2 years for all 103 patients was
6% (Figure 2B).
urvival
Sixty-ﬁve of 103 patients were alive between 6 and
4.7 months (median, 21.4 months) after HCT. The
robability of 2-year survival was 58% (Figure 3). The
aplan-Meier probability of 2-year survival for patients
ith lymphoproliferative diseases (NHL and HD, CLL,
nd Waldenström macroglobulinemia) was 56%; mul-
iple myeloma, 55%; acute leukemias, 68%; CML,
5%; and MDS/MPS, 33%.
tatus of Underlying Disease and
rogression-Free Survival
Fifty of the 65 surviving patients were in complete
igure 2. Cumulative probabilities of grades II, III, IV acute
VHD (A) and chronic extensive GVHD (B) between patients
iven MMF twice (BID) and 3 times (TID) daily.emission (CR), 3 were in partial remission, 4 had M
60table disease, and 8 had relapsed or progressed dis-
ase. Nineteen patients (18.5%) died from disease
elapse or progression. The Kaplan-Meier estimate of
-year progression-free survival for the 103 patients
as 49% (Figure 3). Disease responses were seen
mong all disease categories. Among the 61 patients
ith measurable disease at HCT, the overall response
ate was 60%, with 29 (48%) achieving CR, 7 (12%)
chieving partial remission, 7 (12%) having stable dis-
ase, and 3 not being evaluable because of early non-
elapse deaths. Fifteen (25%) of the 61 patients with
easurable disease at HCT had disease progression,
ncluding all 4 renal cell carcinoma patients. Two
atients who achieved CR eventually relapsed. Eleven
26%) of the 42 patients who were in CR (without
easurable disease) at HCT had disease relapse after
CT. The 1- and 2-year cumulative probabilities of
elapse/progression were 26% and 31%, respectively.
he 2-year Kaplan-Meier estimates of progression-
ree survivals for patients were as follows: lymphopro-
iferative diseases (NHL and HD, CLL, and Walden-
tröm macroglobulinemia), 49%; multiple myeloma,
6%; acute leukemias, 66%; CML, 30%; and MDS/
PS, 25%.
onor Lymphocyte Infusions
Seven of the 103 patients received DLI with a
tarting dose of 107 CD3 cells per kilogram, 5 for
rogressive disease (HD, n  2; MDS, n  2; and
enal cell carcinoma, n  1). The MDS and renal cell
arcinoma patients continued to progress. The HD
atients received cytoreductive chemotherapy before
LI: 1 had stabilization of disease, whereas the other
howed progression. One patient with persistent fol-
icular NHL received a dose of pentostatin 10 mg/m2
days before DLI for low donor T-cell chimerism
35%) at both day 28 and day 44. The patient devel-
ped progressively increasing T-cell chimerism and
igure 3. Kaplan-Meier product estimates of overall and progres-
ion-free survivals for 103 patients given unrelated donor HCT and
MF 3 times daily.
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Nonmyeloablative Unrelated Donor Transplantation
Bxperienced a CR but has required therapy for GVHD
nd infections. The ﬁnal patient had CR of the un-
erlying CLL but developed Epstein-Barr virus lym-
hoproliferative disease in donor cells, which was rap-
dly progressive and only transiently responded to
ultiagent chemotherapy. After DLI, the patient
chieved a CR, as assessed by positron emission and
omputed tomography scans, but has required treat-
ent for GVHD and infections.
LA Class I Allele-Level Mismatching
Of the 10 patients with HLA class I allele mis-
atches, 7 had bidirectional mismatches in both the
VHD and rejection vectors, and 3 had unidirec-
ional mismatches in the rejection vector. One of the
0 patients with single HLA-C allele–mismatched
rafts in the rejection vector for CML-CP rejected the
raft. The distribution of grades II, III, and IV acute
VHD among the patients who had mismatched
rafts was 50%, 10%, and 10%, respectively.
omparison of Results in Current Patients Given
MF 3 Times Daily (n  103) with Those in
revious Patients Given MMF Twice Daily (n  71)
Nonhematopoietic toxicities in the ﬁrst 100 days after
CT. No signiﬁcant differences in overall grade III or
able 3. Comparison of Grade 3 and 4 Organ Toxicities during the
irst 100 Days between Patients Who Received MMF Twice Daily and
hree Times Daily
Organ System
No. Grade III-IV Toxicities*
P Value
Twice Daily
(n  71)
3 Times Daily
(n  103)
ardiovascular 21 (30%) 18 (17%) .06
ndocrine 0 (0%) 1 (1%) .30
astrointestinal 5 (7%) 10 (10%) .53
emorrhage 5 (7%) 7 (7%) .95
epatic 13 (18%) 34 (33%) .03
etabolic 0 (0%) 3 (3%) .07
eurologic 8 (11%) 11 (11%) .90
ulmonary 14 (20%) 18 (17%) .71
enal/genitourinary 3 (4%) 11 (11%) .11
econd malignancy 0 (0%) 1 (1%) .30
ny grade III/IV 37 (52%) 60 (58%) .42
Toxicity was assessed by using the modiﬁed Common Toxicity
Criteria of the National Institutes of Health.
able 4. Infection Rates per 100 Days after HCT for Patients Receivin
Variable
Unadjuste
MMF Twice Daily† MMF 3 Times Daily
ocumented 1.5 2.1
Viral 0.53 0.86
Fungal 0.11 0.26
Bacterial 0.91 1.05
linical 0.15 0.88
Adjusted for patient age and disease risk.
Infection rates per 100 days.
B&MTV nonhematopoietic toxicities were found (Table 3).
atients given MMF 3 times daily had more hepatic
nd metabolic toxicities but fewer cardiac grade III or
V toxicities.
Hematopoietic toxicities and transfusions in the ﬁrst
00 days after HCT. No statistical differences in the
egrees or durations of thrombocytopenias or neutro-
enias were seen. However, the neutrophil nadir was
ower for patients given MMF 3 times daily compared
ith twice daily (100 versus 200 cells per microliter,
espectively; P  .05). Median numbers of platelet
2 [range, 0-48] versus 0 [range, 0-84], respectively;
 .91) and RBC (6 [range, 0-32] versus 7 [range,
-40 days], respectively; P  .66) transfusions in the
rst 100 days after HCT were not signiﬁcantly differ-
nt.
Infectious complications in the ﬁrst 100 days after
CT. Patients who received MMF 3 times daily had
ncreased rates of documented infections (P  .004)
ttributable to higher viral (including cytomegalovirus
eactivation; P  .01) and fungal (P  .02), but not
acterial (P  .36), infections (Table 4). MMF
-times-daily patients also had higher rates of pre-
umed clinical infections (P .0001) for which patho-
enic organisms were not isolated. This remained
igniﬁcant even after correction for patient age and
isease risk.
Graft rejection. Patients given MMF 3 times daily
xperienced fewer rejections (5/103 [5%] versus 13/71
18%]; P  .004; Figure 4). This was true for 3-times-
aily patients both with (P  .08) and without (P 
05) preceding chemotherapy. Multivariate analysis of
he combined data from both patient groups showed
igniﬁcantly increased risks of graft rejection for pa-
ients with CML (hazard ratio, 9.09; conﬁdence inter-
al, 3.0-27) and MDS/MPS (hazard ratio, 3.45; con-
dence interval, 1.0-11) compared with all other
iagnoses (P  .0006; Figure 4). In this model, MMF
times daily resulted in a trend toward lessened graft
ejection (P  .11).
Correlation of day 28 donor T-cell chimerism levels and
utcomes. Patients given MMF 3 times daily had a
tatistically signiﬁcantly higher median level of donor
-cell chimerism at day 28 (90% versus 75%, respec-
ively; P  .02). An analysis of combined data from all
Twice Daily or Three Times Daily
Adjusted*
Relative Risk P Value Relative Risk P Value
1.4 .004 1.4 .01
1.6 .01 1.6 .03
2.4 .02 2.4 .04
1.2 .36 1.1 .48
5.8 <.0001 6.4 <.0001g MMF
d
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474 patients showed that patients with 50% donor
-cell chimerism had (1) a greater risk of eventual
raft rejection (P .0001); (2) lower risks of acute and
hronic GVHD (P  .02 and .0002, respectively); (3)
higher risk of relapse (P  .05); and (4) a trend
oward worse progression-free survival (P  .11).
o correlations between donor T-cell chimerism
evels and survival (P  .78) or nonrelapse mortality
P  .95) were found.
Acute and chronic GVHD. There were no differ-
nces in the times of onset and the cumulative inci-
ences of grades II to IV (P  .37) or III to IV (P 
91) acute GVHD (Figure 2A). Also, both times of
nset and cumulative incidences (P  .46; Figure 2B)
f chronic extensive GVHD were similar.
We next examined risk factors for acute and
hronic GVHD among all 174 G-PBMC recipients.
aving 2 prior chemotherapy regimens (P  .04)
as associated with a higher risk of grades III or IV
cute GVHD. Both numbers of prior chemotherapies
nd greater patient age were strongly associated with
reater risks of chronic GVHD necessitating therapy
P  .0002 and .005, respectively). To determine
hether reduction of host lymphocytes by chemother-
py before HCT could explain the higher incidence of
cute GVHD among patients with 3 compared
o 3 prior chemotherapy regimens, lymphocyte
ounts between day7 and day4 were averaged and
ound to be 790 and 1060 /L, respectively (P  .04).
Nonrelapse mortality, relapse/progression, and progres-
ion-free survival. No differences in nonrelapse mor-
ality were seen (P  .79). There was a trend toward
ess relapse/progression for patients given MMF 3
imes daily (P  .08).
ISCUSSION
The postgrafting immunosuppression with MMF
igure 4. Cumulative probability estimates of rejection for 174
-PBMC recipients given MMF twice (BID) or 3 times (TID)
aily.nd CSP in the current nonablative HCT protocol has t
62een aimed not only at controlling GVHD, but also,
s clearly shown in preclinical canine studies [2], at
acilitating allogeneic engraftment. The previously
ublished study of unrelated HCT used twice-daily
osing of MMF [1]. The 18% incidence of graft re-
ection in G-PBMC recipients, coupled with an unex-
ected short half-life of only 3 hours of the active
MF metabolite, mycophenolic acid (MPA), sug-
ested that increased MMF dosing by using a 3-times-
aily schedule might reduce the incidence of graft
ejection and, moreover, reduce acute GVHD. How
uccessful has this intervention been? The sustained
ngraftment rate for G-PBMC recipients increased
rom 82% to 95% (P  .004). Speciﬁcally, durable
ngraftment for patients with and without chemother-
py increased from 90% to 97% and from 47% to
3%, respectively. The predetermined end point of
chieving a rejection rate of 10% was statistically
emonstrated (P  .05) for patients with prior che-
otherapy, but for those without such therapy, the
nd point of 20% was not achieved with sufﬁcient
tatistical power in this small patient subgroup. We
elieve that the data are strong enough to advocate
hat patients given unrelated donor HCT after FLU/
-Gy TBI conditioning should receive 3-times-daily
MF. However, patients without preceding chemo-
herapy, in particular CML patients, will require, in
ddition, more intensive pretransplantation immuno-
uppressive conditioning to achieve acceptable rates
90%) of donor engraftment [14-16], and a TBI
ose-escalation protocol has been initiated to deter-
ine the level of immunosuppression required.
We evaluated plasma concentrations of MPA, the
ctive metabolite of MMF, and outcomes in 38 pa-
ients of the previous study given MMF 15 mg/kg
wice daily and 47 patients of the current study given
MF 15 mg/kg 3 times daily. MPA pharmacokinetics
ere determined on days 7 and 21. Comparing the
wice-daily and 3-times-daily MMF group, the mean
otal MPA concentration steady states (Css) were 1.9
nd 3.1 g/mL and the unbound Css were 18 and 36
g/mL, respectively (P  .0001) [17]. Sixteen of the
atients who had total MPA Css 3 g/mL had low
50%) donor T-cell chimerism (P  .03), and 6 of
he patients with MPA Css 2.5 g/mL had graft
ejection. We concluded that 3-times-daily dosing of
MF led to increased MPA Css, which, in turn,
redicted higher degrees of donor T-cell chimerism.
iven the strong association between high levels of
onor T-cell chimerism and sustained engraftment
18], targeting MPA Css 2.5 g/mL could prevent
raft rejection.
In contrast to the apparent beneﬁt on engraft-
ent, MMF 3-times-daily dosing did not improve
cute GVHD; the overall and individual grade II, III,
nd IV incidences of acute GVHD were similar to
hose seen on the original MMF twice-daily protocol.
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Nonmyeloablative Unrelated Donor Transplantation
Bhe reasons for the lack of effect on GVHD were not
lear. Nevertheless, the relatively low rates of grade
II or IV acute GVHD seen with both twice-daily and
times a day MMF dosing (10% and 12%, respec-
ively) compared favorably to the 30% to 47% rates
bserved after conventional unrelated donor HCT
19,20]. We have recently reported that there was no
eneﬁcial relationship between acute GVHD (as op-
osed to chronic GVHD) and GVT responses after
onmyeloablative conditioning, but grade III or IV
cute GVHD signiﬁcantly increased nonrelapse mor-
ality [7]. Therefore, future trials will focus on further
educing the incidence of acute GVHD after unre-
ated nonablative HCT.
Besides increased infections in patients given
MF, the total incidences of grade III or IV organ
oxicities were similar in both patient groups. Fortu-
ately, the higher infection rates did not translate into
ncreased nonrelapse mortality. Perhaps the increase
n infections was due to maintaining full-dose MMF
-times-daily patients who developed GVHD with
onsequent greater impairment of host immune re-
ponses. Gastrointestinal and hematologic toxicities
ere not increased in patients given MMF 3 times
aily except for slightly lower neutrophil nadirs. The
easons for the differences in grade III or IV cardio-
ascular and hepatic toxicities between protocols were
ot clear but could have been related to differences in
re-HCT organ comorbidities [19,21].
Given that acute and chronic GVHD were not
educed and that infections increased in MMF
-times-daily patients, the duration of 3-times-daily
MF dosing might be shortened from 96 to 28 days.
urable engraftment was highly correlated with the
resence of 50% donor T-cell chimerism levels at
ay 28 [18,22], and 3-times-daily dosing could safely
e converted to twice-daily dosing in patients with
50% donor T-cell levels at 4 weeks.
This study showed a tumor response rate of 60%
48% CR) in patients with measurable disease at the
ime of HCT, and the cumulative probability of re-
apse at 2 years was 31% in these patients, similar to
he 27% rate in patients who were in CR before HCT.
hese rates were better than those seen in previous
atients given MMF twice daily [1] and argue that
reater immunosuppression with MMF 3 times daily
id not blunt GVT effects. Overall, this translated
nto trends toward decreased relapse/progression and
etter overall and progression-free survivals for pa-
ients treated with MMF 3 times daily. In part, the
mproved tumor control might have been the result of
he higher observed donor chimerism levels [18] and
etter sustained engraftment rates. In part, the nature
f the underlying diseases might have played a role,
ecause patients with myeloid malignancies, such as
DS, MPS, and CML, who had the highest risks of g
B&MTelapse, were more commonly represented on the
MF twice-daily protocol.
The overall analyses of data from the combined
ohort of all 174 G-PBMC recipients conﬁrmed ear-
ier observations of the effects of high levels (50%)
f day 28 donor T-cell chimerism on sustained en-
raftment, on acute and chronic GVHD, and on dis-
ase relapse [1,18]. Also, more heavily pretreated pa-
ients had a moderately increased risk for grade III or
V acute GVHD and had a substantially higher risk
or chronic extensive GVHD. Older patient age was
ndependently associated with a higher risk for chronic
xtensive GVHD. Age has been a well-described risk
actor for acute and chronic GVHD after conventional
CT in patients with hematologic malignancies [23]
nd for chronic, but not acute, GVHD in patients who
ndergo transplantation for aplastic anemia [24,25]. A
igher number of prior chemotherapy regimens pos-
ibly reﬂected lower numbers of intact host immune-
egulatory cells, and this was crudely shown by lower
ymphocyte counts in patients who received 3 che-
otherapy regimens compared with those with less
hemotherapy. The lack of intact host regulatory T-
ell responses has been thought to result in more rapid
onor T-cell engraftment and homeostatic prolifera-
ion [26,27], thus resulting in reduced tolerance in-
uction [28].
The results of this study seemed comparable to
hose of others that used more intensive reduced-
ntensity conditioning regimens, as shown in Table 5.
ost studies were small, including 50 patients. De-
pite more intensive pretransplantation conditioning
nd, in some studies, the addition of in vivo T-cell
epletion with antithymocyte globulin or alemtu-
umab, the graft rejection rates ranged from 4.5% to
3%, which was not better than the results with the
urrent nonmyeloablative regimen. Similar to our
tudy, higher-than-expected graft rejection rates
23%) were identiﬁed for CML patients given high-
ose-rate single exposure of 550-cGy TBI combined
ith FLU. The rates of grade II to IV acute and
hronic GVHD in these studies have ranged from 6%
o 60% and 0% to 59%, respectively, and have gen-
rally been lower after in vivo alemtuzumab. The
urrent nonrelapse mortality rate (19%) was at the
ower end of rates reported in these studies (range,
9.8%-55%). The overall and progression-free sur-
ivals at 2 years of 58% and 49%, respectively, for
urrent patients given MMF 3 times daily seemed
omparable to the corresponding rates of 44% to 76%
nd 37% to 62%, respectively, identiﬁed at 1 to 2
ears in these other studies.
In summary, FLU 90 mg/m2 and 2-Gy TBI condi-
ioning followed by postgrafting immunosuppression
ith CSP twice daily and MMF 3 times daily was highly
ffective for achieving unrelated donor G-PBMC en-
raftment in patients with malignancies except for
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46hose with CML, and this has now become the stan-
ard approach for unrelated HCT after this particular
onmyeloablative regimen. For CML patients, a TBI
ose-escalation study will determine the minimal dose
f TBI necessary for reliable engraftment. Although
ates of grades III and IV acute GVHD were relatively
ow, a further reduction in GVHD and associated
orbidity and mortality would be desirable before
xtending the application of this regimen to patients
ith nonmalignant disorders of hematopoiesis.
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